INNOCAN PHARMA Corp

Total Valuation

INNOCAN PHARMA Corp carries a market capitalization of 7.20M, placing it among publicly traded companies globally. Its enterprise value stands at 19.78M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Share Statistics

INNOCAN PHARMA Corp currently has 4.50M shares outstanding.

Valuation Ratios

The price-to-sales ratio is 0.88, and the price-to-book ratio stands at -0.60.

Enterprise Valuation

On an enterprise value basis, INNOCAN PHARMA Corp trades at an EV/EBITDA multiple of 56.83 and an EV/FCF ratio of 83.56. The EV/Sales ratio of 0.78 reflects the premium investors are willing to pay for the company's revenue stream, while the EV/EBIT multiple of 62.90 provides insight into valuation relative to core operating earnings.

Financial Position

INNOCAN PHARMA Corp maintains a current ratio of 5.51, meaning it holds 5.5x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 17.89, indicating elevated leverage, while an interest coverage ratio of -177.86 demonstrates limited ability to service its debt obligations.

Financial Efficiency

Taxes

Stock Price Statistics

INNOCAN PHARMA Corp's stock has declined approximately -83.2636% over the past 52 weeks. The 50-day moving average sits at 13.01, while the 200-day moving average is 13.01.

Income Statement

Over the trailing twelve months, INNOCAN PHARMA Corp generated 25.28M in revenue and converted that into -1.51M in net income, yielding earnings per share of -0.22. EBITDA reached -2.49M, while operating income came in at -2.53M.

Balance Sheet

INNOCAN PHARMA Corp holds 6.63M in cash and equivalents against 1.42M in total debt, resulting in a net debt position of -5.21M. Total book value stands at -37.00M, with working capital of 8.81M providing operational flexibility.

Cash Flow

INNOCAN PHARMA Corp produced -379,000.00 in operating cash flow over the past twelve months. After subtracting -11,000.00 in capital expenditures, free cash flow totaled -390,000.00 - equivalent to -0.09 per share.

Margins

INNOCAN PHARMA Corp operates with a gross margin of 89.81, reflecting its pricing power and cost economics. The operating margin of -10.01 and net profit margin of -5.99 provide insight into operational efficiency.

Dividends & Yields

Stock Splits

INNOCAN PHARMA Corp's most recent stock split took place on September 5, 2025 with a 65:1 split ratio.

Scores

INNOCAN PHARMA Corp posts an Altman Z-Score of 2.34, near the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.